Several Shh pathway inhibitors have been developed, including cyclopamine, a natural product inhibitor of Smo, and GANT61, a small molecule inhibitor of Gli1. However, these inhibitors have limitations, such as poor pharmacokinetic properties or limited efficacy. Therefore, there is a need for the development of more effective and selective Shh pathway inhibitors.
Rated at less than 0.001%, the SONE-220 ensures that the sound coming out of your speakers is an exact replica of the input signal. SONE-220
SONE-220 exhibits potent inhibitory activity against Shh signaling, with an IC50 value of 220 nM in a cell-based assay. The compound effectively blocks Shh-induced Gli1 expression, cell proliferation, and tumor growth in vitro and in vivo. SONE-220 also shows good selectivity against other signaling pathways, including the Wnt/β-catenin and Notch pathways. Ultra-Low Total Harmonic Distortion (THD): Rated at less
: Maintaining the SONE-220 software ensures the hardware can access the latest improvements and newly released features as they become available from the manufacturer. or specific instructions for navigating the UTI-TOOL software SONE-220 also shows good selectivity against other signaling
SONE-220 is a novel small molecule inhibitor of the Shh pathway that exhibits potent inhibitory activity and good selectivity. The compound shows good pharmacokinetic properties and in vivo efficacy in a medulloblastoma mouse model. These findings suggest that SONE-220 is a promising candidate for the treatment of Shh-driven cancers.